Biogen’s sales and profit will decline this year, but the commercial launches of an Alzheimer’s treatment and a new medicine for depression are expected to help the company return to growth, newly appointed CEO Chris Viehbacher said Wednesday.
Stelios Papadopoulos, the longtime chairman of Biogen’s board, will also be stepping down this year due to the company’s mandatory retirement age policy, Viehbacher said.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
